

# The RIGHT Trial: Rapid Intervention with Glyceryl trinitrate (GTN) in Hypertensive stroke Trial

<b>Submission date</b> 18/02/2008	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 09/05/2008	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 21/08/2015	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims.

The first few hours following a stroke are critical as there may be brain cells that are at the risk of dying but may still be saved. High blood pressure following stroke is common and may impact negatively on the survival of these brain cells. Trials that have assessed the effect of lowering blood pressure following a stroke however have not shown any benefit, but this may be because treatment was often delayed by several hours by the time patients were seen in the hospital. Our goal is to assess the feasibility of using the ambulance services to deliver acute stroke treatments. In this study, paramedics will treat patients with glyceryl trinitrate (GTN), a drug that dilates blood vessels and reduces blood pressure, within 4 hours of stroke. The study will also provide important information on the effects of GTN in very acute strokes.

### Who can participate?

We aim to recruit 80 patients with a stroke who are within 4 hours of onset and also have high blood pressure. Only patients who are seen by our trained paramedics in the Nottingham City, UK district will be included in the study.

### What does the study involve?

Patients will be randomly allocated to receive either a dressing containing GTN or a standard gauze dressing. Paramedics will then measure the patients' blood pressure 10-15 minutes after the dressing is applied. Once in the hospital more detailed information will be given and if patients agree to continue in the study, the treatment will be continued daily for 7 days. Researchers will check the blood pressure every day and perform clinical assessments after completion of 7 days treatment. The final follow up is at 3 months and a member of the research team will do a face to face assessment of the patient, check on their condition, and ask questions about mobility, mood, memory and quality of life.

### What are the possible benefits and risks of participating?

There may be no direct benefit for patients taking part in the study. The information we get from patients' involvement may benefit other people who may have a stroke in the future. All drugs have the possibility of side effects. The side effects from GTN are generally mild. They can

include headache, low blood pressure and dizziness. Patients will be monitored and asked to inform the treating doctor or member of the research team if they feel they have a reaction to the medication.

Where is the study run from?

The Division of Stroke, University of Nottingham.

When is the study starting and how long is it expected to run for?

The study started recruitment in February 2010 and is expected to run until the end of December 2011.

Who is funding the study?

The Nottingham University Hospitals NHS Trust Research and Development, The Division of Stroke, University of Nottingham.

Who is the main contact?

Professor Philip Bath

Philip.bath@nottingham.ac.uk

Dr Sandeep Ankolekar

Sandeep.ankolekar@nottingham.ac.uk

#### **Study website**

<http://www.right-trial.org/>

## **Contact information**

#### **Type(s)**

Scientific

#### **Contact name**

Prof Philip Bath

#### **Contact details**

Division of Stroke Medicine

University of Nottingham

Clinical Sciences Building

City Hospital

Hucknall Road

Nottingham

United Kingdom

NG5 1PB

+44 (0)115 823 1765

philip.bath@nottingham.ac.uk

## **Additional identifiers**

#### **EudraCT/CTIS number**

2007-004766-40

#### **IRAS number**

ClinicalTrials.gov number

Secondary identifying numbers

N/A

## Study information

### Scientific Title

Determining the potential of ambulance-based randomised controlled trials in patients with hyperacute stroke: assessment of glyceryl trinitrate in lowering blood pressure

### Acronym

RIGHT

### Study objectives

1. To assess the feasibility of performing an ambulance-based trial in patients with hyperacute stroke, a key question for the future testing of potential interventions aimed at neuroprotection and physiological control
2. To assess the effect of glyceryl trinitrate (GTN) on blood pressure (BP) in this setting

On 05/11/2012 the overall trial end date was changed from 31/12/2011 to 15/03/2012.

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Nottingham research ethics committee, 08/04/2009, ref: 09/H0408/5

### Study design

Single-blind randomised controlled trial with blinded outcome assessment

### Primary study design

Interventional

### Secondary study design

Randomised controlled trial

### Study setting(s)

Hospital

### Study type(s)

Treatment

### Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet.

### Health condition(s) or problem(s) studied

Acute stroke

## **Interventions**

Transdermal GTN (5 mg) or no patch.

Total duration of treatment: 7 days

Total duration of follow up: 90 days

## **Intervention Type**

Drug

## **Phase**

Not Applicable

## **Drug/device/biological/vaccine name(s)**

Glyceryl trinitrate

## **Primary outcome measure**

To assess the feasibility of using the ambulance service to test and deliver treatment for stroke in the hyperacute setting, will be measured as effects of GTN on blood pressure at 2 hours post-treatment.

## **Secondary outcome measures**

Current secondary outcome measures as of 05/11/2012:

Haemodynamic outcomes

1. BP and heart rate (HR) at 15 minutes (in ambulance), 120 minutes (at hospital) and on days 2-7.

BP/HR derivatives were calculated as follows:

Pulse pressure (PP) = systolic BP (SBP) - diastolic BP (DBP)

Rate pressure product = SBP x HR

2. Central BP and aortic compliance (Augmentation Index) were at 120 minutes

Clinical outcomes

1. Impairment (Scandinavian Stroke Scale, SSS) at 2 hours and day 7.

2. Other measurements at day 7 included

2.1. Recurrence

2.2. Death

2.3. Headache

2.4. Hypotension

2.5. Neurological deterioration (defined as a 5 point reduction in the SSS from Day 1 to Day 7).

3. Final clinical functional outcomes were recorded at day 90 including

3.1. Dependency (modified Rankin Scale, mRS),

3.2. Disability (Barthel Index, BI),

3.3. Cognition (Mini Mental State Examination, MMSE),

3.4. Mood (Zung Depression Index, ZDI), and

3.5. Quality of life (EuroQoL, as EQ-5D and EQ-VAS).

Ambulance trial logistics outcomes

1. Recruitment rate

2. Protocol violations

3. Final diagnosis

4. Timings between ictus, paramedic arrival and departure

5. Arrival at hospital

Previous secondary outcome measures until 05/11/2012:

To assess the effects of GTN on:

1. Blood pressure
2. Pulse pressure (PP)
3. Rate pressure product (RPP)
4. Surrogate markers of efficacy in blood in the hyperacute setting

Measured in hospital, day 7/discharge/death, and day 90.

**Overall study start date**

01/03/2008

**Completion date**

15/03/2012

## **Eligibility**

**Key inclusion criteria**

1. Adult patients of either sex; greater than 40 years of age
2. Paramedic assessment of stroke on basis of positive Face & Arm weakness and Speech abnormality Test (FAST) in the context of a call to a patient with a possible acute stroke
3. Event less than 4 hours of onset (sleep stroke - onset as bed time)
4. High systolic BP (greater than 140 mmHg)

**Participant type(s)**

Patient

**Age group**

Adult

**Sex**

Both

**Target number of participants**

80 (41 by end of recruitment in December 2011)

**Key exclusion criteria**

1. No consent/assent is available
2. GTN is indicated (e.g. concurrent angina)
3. GTN is contraindicated (e.g. dehydration, hypovolaemia)
4. Aged less than 40 years
5. Coma; Glasgow Coma Scale (GCS) score less than or equal to 8
6. History of seizures
7. Non-ambulatory pre-morbidly (modified Rankin scale of greater than 2)
8. Hypoglycaemia (if glucose tested)
9. Patients from a nursing home

**Date of first enrolment**

01/02/2010

**Date of final enrolment**

01/12/2011

**Locations****Countries of recruitment**

England

United Kingdom

**Study participating centre**

**University of Nottingham**

Nottingham

United Kingdom

NG5 1PB

**Sponsor information****Organisation**

University of Nottingham (UK)

**Sponsor details**

c/o Mr Paul Cartledge

Head of Research Grants and Research Innovation Services

Kings Meadow Campus

Lenton Lane

Nottingham

England

United Kingdom

NG7 2NR

+44 (0)115 951 5670

Paul.cartledge@nottingham.ac.uk

**Sponsor type**

University/education

**Website**

<http://www.nottingham.ac.uk/>

**ROR**

<https://ror.org/01ee9ar58>

**Funder(s)**

**Funder type**

University/education

**Funder Name**

Nottingham University Hospitals NHS Trust (Research & Development Pump Priming competition)

**Funder Name**

The Division of Stroke, University of Nottingham

## Results and Publications

**Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date****Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Protocol article</a>	protocol	01/11/2012		Yes	No
<a href="#">Results article</a>	results	01/11/2013		Yes	No
<a href="#">HRA research summary</a>			28/06/2023	No	No